CAMBRIDGE, MA, SURGE Therapeutics, a biotech company pioneering the delivery of immunotherapy during cancer surgery, announced a $32 million Series B funding round.
SURGE Therapeutics, a biotech company pioneering the delivery of immunotherapy during cancer surgery, announced a $32 million Series B funding round led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango HealthTech.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
